MedTrace Logo

Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)

NCT00000135 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2015-11-17

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of a human anti-CMV monoclonal antibody, MSL-109, as adjunct therapy for controlling CMV retinitis.

Conditions

  • HIV Infections
  • Cytomegalovirus Retinitis

Interventions

DRUG

MSL-109

60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.

OTHER

Placebo

60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.

Sponsors & Collaborators

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-09-30
Primary Completion
1996-08-31
Completion
1996-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000135 on ClinicalTrials.gov